• Je něco špatně v tomto záznamu ?

Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS"

MO. Grimm, AG. van der Heijden, M. Colombel, T. Muilwijk, L. Martínez-Piñeiro, MM. Babjuk, LN. Türkeri, J. Palou, A. Patel, AS. Bjartell, C. Caris, RG. Schipper, WPJ. Witjes, EAU Research Foundation NIMBUS Study Group

. 2020 ; 78 (5) : 690-698. [pub] 20200520

Jazyk angličtina Země Švýcarsko

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026447

BACKGROUND: Intravesical instillation of bacillus Calmette-Guérin (BCG) is an accepted strategy to prevent recurrence of non-muscle-invasive bladder cancer (NMIBC) but associated with significant toxicity. OBJECTIVE: NIMBUS assessed whether a reduced number of standard-dose BCG instillations are noninferior to the standard number and dose in patients with high-grade NMIBC. DESIGN, SETTING, AND PARTICIPANTS: A total of 345 patients from 51 sites were randomised between December 2013 and July 2019. We report results after a data review and safety analysis by the Independent Data Monitoring Committee based on the cut-off date of July 1, 2019. INTERVENTION: The standard BCG schedule was 6 wk of induction followed by 3 wk of maintenance at 3, 6, and 12 mo (15 instillations). The reduced frequency BCG schedule was induction at wks 1, 2, and 6 followed by 2 wk (wks 1 and 3) of maintenance at 3, 6, and 12 mo (nine instillations). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was time to first recurrence. Secondary endpoints included progression to ≥ T2 and toxicity. RESULTS AND LIMITATIONS: In total, 170 patients were randomised to reduced frequency and 175 to standard BCG. Prognostic factors at initial resection were as follows: Ta/T1: 46/54%; primary/recurrent: 92/8%; single/multiple: 57/43%; and concomitant carcinoma in situ: 27%. After 12 mo of median follow-up, the intention-to-treat analysis showed a safety-relevant difference in recurrences between treatment arms: 46/170 (reduced frequency) versus 21/175 patients (standard). Additional safety analyses showed a hazard ratio of 0.40 with the upper part of the one-sided 97.5% confidence interval of 0.68, meeting a predefined stopping criterion for inferiority. CONCLUSIONS: The reduced frequency schedule was inferior to the standard schedule regarding the time to first recurrence. Further recruitment of patients was stopped immediately to avoid harm in the reduced frequency BCG arm. PATIENT SUMMARY: After surgical removal of the tumour, patients with high-grade non-muscle-invasive bladder cancer are treated with bacillus Calmette-Guérin to prevent recurrence and progression. This is associated with significant side effects. We report the results of a clinical trial showing a reduction in the number of instillations (from 15 to nine in total) being inferior to the standard protocol. From today's perspective, complete tumour resection and a standard number of instillations remain the standard of care.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026447
003      
CZ-PrNML
005      
20211026132912.0
007      
ta
008      
211013s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2020.04.066 $2 doi
035    __
$a (PubMed)32446864
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Grimm, Marc-Oliver $u Department of Urology, Jena University Hospital, Jena, Germany. Electronic address: marc-oliver.grimm@med.uni-jena.de
245    10
$a Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS" / $c MO. Grimm, AG. van der Heijden, M. Colombel, T. Muilwijk, L. Martínez-Piñeiro, MM. Babjuk, LN. Türkeri, J. Palou, A. Patel, AS. Bjartell, C. Caris, RG. Schipper, WPJ. Witjes, EAU Research Foundation NIMBUS Study Group
520    9_
$a BACKGROUND: Intravesical instillation of bacillus Calmette-Guérin (BCG) is an accepted strategy to prevent recurrence of non-muscle-invasive bladder cancer (NMIBC) but associated with significant toxicity. OBJECTIVE: NIMBUS assessed whether a reduced number of standard-dose BCG instillations are noninferior to the standard number and dose in patients with high-grade NMIBC. DESIGN, SETTING, AND PARTICIPANTS: A total of 345 patients from 51 sites were randomised between December 2013 and July 2019. We report results after a data review and safety analysis by the Independent Data Monitoring Committee based on the cut-off date of July 1, 2019. INTERVENTION: The standard BCG schedule was 6 wk of induction followed by 3 wk of maintenance at 3, 6, and 12 mo (15 instillations). The reduced frequency BCG schedule was induction at wks 1, 2, and 6 followed by 2 wk (wks 1 and 3) of maintenance at 3, 6, and 12 mo (nine instillations). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was time to first recurrence. Secondary endpoints included progression to ≥ T2 and toxicity. RESULTS AND LIMITATIONS: In total, 170 patients were randomised to reduced frequency and 175 to standard BCG. Prognostic factors at initial resection were as follows: Ta/T1: 46/54%; primary/recurrent: 92/8%; single/multiple: 57/43%; and concomitant carcinoma in situ: 27%. After 12 mo of median follow-up, the intention-to-treat analysis showed a safety-relevant difference in recurrences between treatment arms: 46/170 (reduced frequency) versus 21/175 patients (standard). Additional safety analyses showed a hazard ratio of 0.40 with the upper part of the one-sided 97.5% confidence interval of 0.68, meeting a predefined stopping criterion for inferiority. CONCLUSIONS: The reduced frequency schedule was inferior to the standard schedule regarding the time to first recurrence. Further recruitment of patients was stopped immediately to avoid harm in the reduced frequency BCG arm. PATIENT SUMMARY: After surgical removal of the tumour, patients with high-grade non-muscle-invasive bladder cancer are treated with bacillus Calmette-Guérin to prevent recurrence and progression. This is associated with significant side effects. We report the results of a clinical trial showing a reduction in the number of instillations (from 15 to nine in total) being inferior to the standard protocol. From today's perspective, complete tumour resection and a standard number of instillations remain the standard of care.
650    _2
$a adjuvancia imunologická $x aplikace a dávkování $7 D000276
650    _2
$a aplikace intravezikální $7 D000283
650    _2
$a BCG vakcína $x aplikace a dávkování $7 D001500
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a prospektivní studie $7 D011446
650    _2
$a referenční standardy $7 D012015
650    _2
$a nádory močového měchýře $x farmakoterapie $x patologie $7 D001749
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a van der Heijden, Antoine G $u Department of Urology, Radboud UMC, Nijmegen, The Netherlands
700    1_
$a Colombel, Marc $u Department of Urology, Hospital Edouard Herriot, Lyon, France
700    1_
$a Muilwijk, Tim $u Department of Urology, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Martínez-Piñeiro, Luis $u Department of Urology, Hospital Universitario La Paz, Madrid, Spain
700    1_
$a Babjuk, Marko M $u Department of Urology, Hospital Motol, Charles University, Prague, Czech Republic
700    1_
$a Türkeri, Levent N $u Department of Urology, Acıbadem University, Istanbul, Turkey
700    1_
$a Palou, Joan $u Urology Department, Fundació Puigvert, Barcelona, Spain
700    1_
$a Patel, Anup $u London, UK
700    1_
$a Bjartell, Anders S $u EAU Research Foundation, Arnhem, The Netherlands; Skåne University Hospital, Lund University, Sweden
700    1_
$a Caris, Christien $u EAU Research Foundation, Arnhem, The Netherlands
700    1_
$a Schipper, Raymond G $u EAU Research Foundation, Arnhem, The Netherlands
700    1_
$a Witjes, Wim P J $u EAU Research Foundation, Arnhem, The Netherlands
710    2_
$a EAU Research Foundation NIMBUS Study Group
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 78, č. 5 (2020), s. 690-698
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32446864 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132918 $b ABA008
999    __
$a ok $b bmc $g 1715231 $s 1146954
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 78 $c 5 $d 690-698 $e 20200520 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace